Cervical Cancer

The Four-type HPV Vaccine Gardasil(R) Demonstrates Real Life Benefits
Results from an observational study in Australia establish that after only one year of a comprehensive vaccination programme with the four-type (6,11,16,18) human papillomavirus (HPV) Gardasil® major benefits are already being seen. The study results will be presented at the 25th International Papillomavirus Conference (IPV) in Malmö, Sweden.

Mother Like Daughter: Maternal Attitude Toward Prevention A Factor In Whether Or Not Daughter Vaccinated For HPV
Mothers' attitudes toward prevention efforts strongly influence their daughters' human papillomavirus (HPV) vaccine uptake among their daughters. Researchers investigated whether maternal attitude toward prevention, as indicated by history of seeking Pap tests and contracting sexually transmitted infections, influenced HPV vaccine uptake among their adolescent daughters.

Must Cervical Screening Be Discontinued At The Age Of Fifty?
According to a study published on bmj.com, since the beginning of planned cervical screening programs which started in Europe more than forty years ago, there have always been debates about the maximum age limit for efficient screening. The study concludes that screening for cervical cancer should not stop after the age of fifty, since the risk is comparable to that of younger women, even following several negative smear results.

Americans May Be Missing Direct Route To Head And Neck Cancer Care According To Survey
Tens of thousands of Americans are diagnosed annually with head and neck cancers, but many adults are unaware of doctors who specialize in treating these conditions, according to a recent survey by the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), the association representing America's ear, nose and throat (ENT) doctors.

Cervical Cancer Vaccine Reaches Vanuatu
A Brisbane team are working closely with the Vanuatu Government to trial a program for effective delivery of cervical cancer vaccines to schoolgirls in resource-poor settings. Headed by cervical cancer vaccine pioneer Professor Ian Frazer from UQ's

BSD Receives FDA Humanitarian Use Designation For The BSD-2000 Hyperthermia System
BSD Medical Corporation (NASDAQ:BSDM) announced that the U.S. Food and Drug Administration (FDA) has granted Humanitarian Use Device (HUD) designation for the company's BSD-2000 Hyperthermia System for use in conjunction with radiation therapy for the treatment of cervical carcinoma patients who are ineligible for chemotherapy.

Americans May Be Missing Direct Route To Head And Neck Cancer Care According To Survey
Tens of thousands of Americans are diagnosed annually with head and neck cancers, but many adults are unaware of doctors who specialize in treating these conditions, according to a recent survey by the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS), the association representing America's ear, nose and throat (ENT) doctors.

Studies Of GARDASIL(R), Merck's Cervical Cancer Vaccine, And HPV 16 Vaccine Component Of GARDASIL Presented At International Papillomavirus Conference
In a study of an extended follow up of 290 women naïve to HPV type 16, the HPV 16 component of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant] was efficacious against HPV 16 infection for an average of 8.5 years after administration. The women enrolled in this study are a subset of the original Phase II HPV 16 proof-of-concept study published in 2002. Follow up ranged from 7.2 years to up to 9.5 years.

Cervical Cancer Risk For Women Over 50
Cervical cancer screening for over 50-year-olds continues to find abnormalities even if they have clear results in their 40s, a new study published by The Institute of Cancer Research (ICR) in the British Journal of Cancer has revealed. The results are from a cohort study of two million women aged between 20 and 64.

Cancer-Causing Virus Associated With Higher Risk Of New HIV Infection
Infection with anal human papillomavirus (HPV), a virus that can cause anal and cervical cancers, is associated with a higher risk of new HIV infection in previously HIV-negative men who have sex with men (MSM), according to new UCSF research. Reported online ahead of print in the journal AIDS, the findings are available now. They are scheduled for publication in an upcoming print issue.

Media Guardian Award For NHS Direct, England
An HPV 'virtual surgery' and web chat service on Habbo Hotel¹, commissioned by the Department of Health and run by NHS Direct to help prepare young girls for the new cervical cancer vaccine, has won a 2009 Media Guardian Innovation Award. The HPV service was aimed at young girls aged 12 to 13 to help answer their questions about the vaccine² throughout September and October 2008. A number of agencies and government departments were involved in the project.

Media Guardian Award For NHS Direct, England
An HPV 'virtual surgery' and web chat service on Habbo Hotel¹, commissioned by the Department of Health and run by NHS Direct to help prepare young girls for the new cervical cancer vaccine, has won a 2009 Media Guardian Innovation Award. The HPV service was aimed at young girls aged 12 to 13 to help answer their questions about the vaccine² throughout September and October 2008. A number of agencies and government departments were involved in the project.

HPV Testing Significantly Reduces Deaths From Cervical Cancer, Compared To Other Methods Including Pap
Results from an eight-year trial involving more than 130,000 women published today in The New England Journal of Medicine (NEJM) demonstrate that in low-resource settings a single round of HPV testing significantly reduces the numbers of advanced cervical cancers and deaths, compared with Pap (cytology) testing or visual inspection with acetic acid (VIA).

Milestone Tumor Virus Publication By Elsevier Journal Virology
A recent special edition of the Elsevier journal Virology, reviews the past, present, and future of the exciting field of small DNA tumor viruses. Many of the leaders in the field, including Dr Harald Zur Hausen, who was honored with the 2008 Nobel Prize in Medicine for his discovery of the role of human papillomaviruses in cervical cancer, contributed to this comprehensive state-of-the-art publication.

CDC To Review Vaccine Policies; Immigrant, Women's Rights Advocates Anticipating Repeal Of HPV Vaccine Requirement
A coalition of more than 100 groups representing women, immigrants, and public health and reproductive rights advocates are hoping CDC will repeal its rule requiring female immigrants seeking U.S. citizenship to receive the human papillomavirus vaccine Gardasil, the

The Four-type HPV Vaccine Gardasil(R) Demonstrates Real Life Benefits
Results from an observational study in Australia establish that after only one year of a comprehensive vaccination programme with the four-type (6,11,16,18) human papillomavirus (HPV) Gardasil® major benefits are already being seen. The study results will be presented at the 25th International Papillomavirus Conference (IPV) in Malmö, Sweden.

HPV Testing Significantly Reduces Deaths From Cervical Cancer, Compared To Other Methods Including Pap
Results from an eight-year trial involving more than 130,000 women published today in The New England Journal of Medicine (NEJM) demonstrate that in low-resource settings a single round of HPV testing significantly reduces the numbers of advanced cervical cancers and deaths, compared with Pap (cytology) testing or visual inspection with acetic acid (VIA).

GSK Submits Final Data For Application To Market HPV Vaccine Cervarix In U.S.
GlaxoSmithKline on Monday said it has submitted final data to FDA in support of its application to market the human papillomavirus vaccine Cervarix in the U.S., the AP/Forbes.com reports (AP/Forbes.com, 3/30).

Landmark Study In The New England Journal Of Medicine Shows HPV Testing Significantly Reduces Deaths From Cervical Cancer
Results from an eight-year trial involving more than 130,000 women published in The New England Journal of Medicine (NEJM) demonstrate that in low-resource settings a single round of HPV testing significantly reduces the numbers of advanced cervical cancers and deaths, compared with Pap (cytology) testing or visual inspection with acetic acid (VIA).

The Four-type HPV Vaccine Gardasil(R) Demonstrates Real Life Benefits
Results from an observational study in Australia establish that after only one year of a comprehensive vaccination programme with the four-type (6,11,16,18) human papillomavirus (HPV) Gardasil® major benefits are already being seen. The study results will be presented at the 25th International Papillomavirus Conference (IPV) in Malmö, Sweden.

CERVARIX(R) U.S. Regulatory Update
GlaxoSmithKline (NYSE: GSK) provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of CERVARIX(R), its vaccine to prevent cervical cancer and cervical pre-cancer related to human papillomavirus types 16 and 18. GSK has submitted final data from its Phase III pivotal efficacy study, HPV-008, to the FDA. The FDA has previously reviewed interim data from the same trial.

Advaxis Updates Phase I Trial Survival Data: 23% Of Patients Still Surviving After 2+ Years
Advaxis, Incorporated (OTCBB: ADXS), has updated survival data for its Phase I trial of its live Listeria vaccine ADXS11-001(formerly named Lovaxin-C) in patients with recurrent, metastatic, carcinoma of the cervix. While the Phase I safety trial was not designed to evaluate efficacy or survival as its primary endpoints, Advaxis has continued to follow the survival of the study participants.

Advaxis Updates Phase I Trial Survival Data: 23% Of Patients Still Surviving After 2+ Years
Advaxis, Incorporated (OTCBB: ADXS), has updated survival data for its Phase I trial of its live Listeria vaccine ADXS11-001(formerly named Lovaxin-C) in patients with recurrent, metastatic, carcinoma of the cervix. While the Phase I safety trial was not designed to evaluate efficacy or survival as its primary endpoints, Advaxis has continued to follow the survival of the study participants.

NYT Examines Debate Over Replacing Pap Smears With HPV Tests For Cervical Cancer Screenings
The New York Times on Tuesday examined the debate among reproductive health experts over whether a new DNA test for human papillomavirus should replace Pap smears as the primary method for screening for cervical cancer.

Milestone Tumor Virus Publication By Elsevier Journal Virology
A recent special edition of the Elsevier journal Virology, reviews the past, present, and future of the exciting field of small DNA tumor viruses. Many of the leaders in the field, including Dr Harald Zur Hausen, who was honored with the 2008 Nobel Prize in Medicine for his discovery of the role of human papillomaviruses in cervical cancer, contributed to this comprehensive state-of-the-art publication.

GSK Submits Final Data For Application To Market HPV Vaccine Cervarix In U.S.
GlaxoSmithKline on Monday said it has submitted final data to FDA in support of its application to market the human papillomavirus vaccine Cervarix in the U.S., the AP/Forbes.com reports (AP/Forbes.com, 3/30).

Advaxis Updates Phase I Trial Survival Data: 23% Of Patients Still Surviving After 2+ Years
Advaxis, Incorporated (OTCBB: ADXS), has updated survival data for its Phase I trial of its live Listeria vaccine ADXS11-001(formerly named Lovaxin-C) in patients with recurrent, metastatic, carcinoma of the cervix. While the Phase I safety trial was not designed to evaluate efficacy or survival as its primary endpoints, Advaxis has continued to follow the survival of the study participants.

Milestone Tumor Virus Publication By Elsevier Journal Virology
A recent special edition of the Elsevier journal Virology, reviews the past, present, and future of the exciting field of small DNA tumor viruses. Many of the leaders in the field, including Dr Harald Zur Hausen, who was honored with the 2008 Nobel Prize in Medicine for his discovery of the role of human papillomaviruses in cervical cancer, contributed to this comprehensive state-of-the-art publication.

CERVARIX(R) U.S. Regulatory Update
GlaxoSmithKline (NYSE: GSK) provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of CERVARIX(R), its vaccine to prevent cervical cancer and cervical pre-cancer related to human papillomavirus types 16 and 18. GSK has submitted final data from its Phase III pivotal efficacy study, HPV-008, to the FDA. The FDA has previously reviewed interim data from the same trial.

CERVARIX(R) U.S. Regulatory Update
GlaxoSmithKline (NYSE: GSK) provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of CERVARIX(R), its vaccine to prevent cervical cancer and cervical pre-cancer related to human papillomavirus types 16 and 18. GSK has submitted final data from its Phase III pivotal efficacy study, HPV-008, to the FDA. The FDA has previously reviewed interim data from the same trial.

HPV Test Effective For Preventing Cervical Cancer Deaths In Some Countries, Study Finds
One round of screening for human papillomavirus can reduce by more than 50% the risk of death from cervical cancer, which can be caused by the virus, according to a study published in the current issue of the New England Journal of Medicine, Time.com reports (Sharples, Time.com, 4/2).